3
NANOTECHNOLOGY-BASED α1-ADRENOCEPTOR/GPR55 BIOMARKER ASSAY: MOLECULAR PROGNOSTIC TEST FOR AGGRESSIVE PROSTATE CANCER ON THE HORIZON?
Authors: Kalyani Chimajirao Patil, Dr Craig J Daly

Number of views: 540
The paramount clinical dilemma in prostate cancer (PCa) management is the search for reliable prognostic markers evaluable on biopsy specimens to enable minimization of intervention, incurring financial and morbidity-related costs. Although, in recent years, the application of next-generation sequencing to hundreds of prostate tumours has defined novel molecular sub-types, the unambiguous demonstration of tumour multifocality, clinical variability and transcriptomic diversity has confounded attempts to achieve diagnostic, prognostic and therapeutic breakthroughs. Currently, the majority of prognostic weight of PCa falls on Gleason grading and score and pre-treatment prostate specific antigen (PSA) levels 1, but in practice, even when combined with predictive nomograms, they do not provide sufficient information to accurately stratify tumours and guide clinical decision-making in patients. The unreliability of such traditional clinical and pathologic prognosticators, gaps in PCa armamentarium and high metastasis-associated deaths has prompted the search for prognostic tumour markers for metastatic behavior to allow discernment of patients who need and warrant radical therapy for aggressive disease from patients enrolled in ‘active surveillance’ group, dramatically reducing unnecessary complications, treatment and health-care costs.